Clinical Trial Update: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing the NOBORI Biolimus-Eluting Stent to XIENCE and PROMUS Everolimus-Eluting Stents in patients with coronary artery disease has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• NOBORI Biolimus-Eluting Stent (Biolimus-eluting stent)
• PROMUS Everolimus-Eluting Stent (Everolimus-eluting stent)
• XIENCE everolimus-eluting stent (everolimus)

Snippet

Sponsor: Takeshi Morimoto | Conditions: Coronary Artery Disease | Phase 4 | Status: COMPLETED